HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D.,

Chief Medical Officer and Malte Peters, M.D., to Board of Directors

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE)

-- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary

arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of

Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023.

"Katia has had a major impact

on HOOKIPA's clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company

in 2021. She will be leading the progression of our clinical programs to the next level, specifically our own programs in head and neck

and prostate cancers and our partnered programs with Gilead and Roche," said Joern Aldag, Chief Executive Officer at HOOKIPA.

"We are also excited to welcome Malte to our Board. With a background in both oncology and infectious disease, Malte's

experience leading dozens of oncology therapies through the clinic to help patients will be invaluable to HOOKIPA as we advance our pipeline

and initiate additional clinical studies."

Dr. Schlienger has been promoted to Chief Medical Officer. She has

served as the Company's Executive Vice President, Clinical Research and Development since July 2022. Prior to that, Dr. Schlienger

served as Senior Vice President, Head of Immuno-Oncology Clinical Research and Development from January 2021 to June 2022. She previously

worked at Merck & Co., for 14 years, serving in roles of increasing responsibility across early and late-stage clinical development

in oncology and vaccines. She received an M.D. from the School of Medicine Lariboisiere Saint-Louis in Paris, France and a Ph.D. in Microbiology/Virology

from Paris Diderot University.

Dr. Peters serves as Chief Research and

Development Officer at MorphoSys and will retire from the company at the end of 2022. He joined MorphoSys in 2017 as Chief Development

Officer. In these roles, he oversaw the company's research and development pipeline, including the design and execution of three

pivotal studies. Prior to joining MorpoSys, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit

of Sandoz in Germany. Dr. Peters also spent 12 years in leadership positions at Novartis Oncology, including Vice President, Clinical

Head and Site Head for Basel, East Hanover and Shanghai. He was responsible for multiple development programs and clinical trials at

Novartis, contributing to the approval of several cancer therapies. Earlier in his career, he held positions at Micromet AG and Merck

KgaA, and also served as a research scientist in infectious disease.

Dr. Peters is a Member of the Board of

Directors at Tango Therapeutics (NASDAQ: TNGX). He is board certified in internal medicine and earned his medical degree from Freie Universit t

in Berlin, with a postdoctoral fellowship in Toronto.

"I am passionate about improving

global health, and I have dedicated my career to making new therapies available to individuals with serious and life-threatening conditions,"

said Dr. Peters. "I'm honored to join the HOOKIPA Board of Directors and look forward to contributing my expertise to help

the company advance its pipeline of novel arenaviral therapeutic candidates so we may have more tools to improve the lives of people

with cancer and chronic infectious disease."

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is

a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform,

which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating

and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing

antibodies. HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus

16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic

for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Forward Looking Statements

Certain statements set forth in this press release constitute "forward-looking"

statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be

identified by terms such as "believes," "expects," "plans," "potential," "would"

or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that

could cause HOOKIPA's research and clinical development programs, future results, performance or achievements to differ significantly

from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties

inherent in the drug development process, including HOOKIPA's programs' early stage of development, the process of designing

and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated

with manufacturing drug products, HOOKIPA's ability to successfully establish, protect and defend its intellectual property, risks

relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact

of COVID-19 on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing

cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description

of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as

well as risks relating to the business of the company in general, see HOOKIPA's quarterly report on Form 10-Q for the quarter ended

September 30, 2022, which is available on the Security and Exchange Commission's website at www.sec.gov and HOOKIPA's website

at www.hookipapharma.com.

Investors and others should note that we announce

material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings,

press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members

and the public about our company, our services and other issues. It is possible that the information we post on social media could be

deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information

we post on the U.S. social media channels listed on our investor relations website.